Regeneron Pharmaceuticals Toekomstige groei
Future criteriumcontroles 1/6
Regeneron Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 11.7% en 8% per jaar. De winst per aandeel zal naar verwachting groeien met 11.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 15% zijn.
Belangrijke informatie
11.7%
Groei van de winst
11.70%
Groei van de winst per aandeel
| Biotechs winstgroei | 25.4% |
| Inkomstengroei | 8.0% |
| Toekomstig rendement op eigen vermogen | 14.99% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 20 May 2026 |
Recente toekomstige groei-updates
Recent updates
Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking Alpha
Narratiefupdate • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.
Narratiefupdate • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.
Narratiefupdate • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.Narratiefupdate • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.Narratiefupdate • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.
Nieuw narratief • Mar 03
Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.
Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.Narratiefupdate • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.Narratiefupdate • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.Narratiefupdate • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.Narratiefupdate • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.Narratiefupdate • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.Narratiefupdate • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.Narratiefupdate • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.Analyseartikel • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...Narratiefupdate • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.Analyseartikel • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...Narratiefupdate • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.Narratiefupdate • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 18,940 | 5,788 | 6,899 | 7,040 | 22 |
| 12/31/2027 | 17,553 | 5,133 | 6,090 | 6,277 | 26 |
| 12/31/2026 | 15,880 | 4,088 | 5,055 | 5,696 | 27 |
| 3/31/2026 | 14,920 | 4,423 | 3,791 | 5,013 | N/A |
| 12/31/2025 | 14,343 | 4,505 | 3,765 | 4,979 | N/A |
| 9/30/2025 | 14,248 | 4,578 | 3,881 | 5,071 | N/A |
| 6/30/2025 | 14,214 | 4,459 | 3,556 | 4,744 | N/A |
| 3/31/2025 | 14,086 | 4,499 | 2,962 | 3,953 | N/A |
| 12/31/2024 | 14,202 | 4,413 | 3,539 | 4,421 | N/A |
| 9/30/2024 | 13,847 | 4,655 | 3,319 | 4,247 | N/A |
| 6/30/2024 | 13,489 | 4,322 | 3,184 | 4,071 | N/A |
| 3/31/2024 | 13,100 | 3,858 | 3,930 | 4,739 | N/A |
| 12/31/2023 | 13,117 | 3,954 | 3,668 | 4,594 | N/A |
| 9/30/2023 | 13,097 | 3,991 | 4,359 | 5,224 | N/A |
| 6/30/2023 | 12,671 | 4,299 | 3,004 | 4,739 | N/A |
| 3/31/2023 | 12,370 | 4,183 | 2,527 | 4,281 | N/A |
| 12/31/2022 | 12,173 | 4,338 | 3,398 | 5,015 | N/A |
| 9/30/2022 | 13,710 | 5,370 | 4,148 | 5,668 | N/A |
| 6/30/2022 | 14,227 | 5,687 | 7,869 | 8,452 | N/A |
| 3/31/2022 | 16,508 | 7,934 | 7,936 | 8,515 | N/A |
| 12/31/2021 | 16,072 | 8,075 | 6,529 | 7,081 | N/A |
| 9/30/2021 | 13,543 | 6,996 | 5,381 | 5,940 | N/A |
| 6/30/2021 | 12,384 | 6,205 | 1,694 | 2,272 | N/A |
| 3/31/2021 | 9,198 | 4,004 | 2,029 | 2,589 | N/A |
| 12/31/2020 | 8,497 | 3,513 | 2,004 | 2,618 | N/A |
| 9/30/2020 | 7,938 | 3,156 | 1,582 | 2,175 | N/A |
| 6/30/2020 | 7,387 | 2,984 | 2,425 | 2,986 | N/A |
| 3/31/2020 | 7,013 | 2,279 | 1,706 | 2,231 | N/A |
| 12/31/2019 | 6,558 | 2,116 | N/A | 2,430 | N/A |
| 9/30/2019 | 6,622 | 2,144 | N/A | 2,371 | N/A |
| 6/30/2019 | 6,542 | 2,069 | N/A | 2,267 | N/A |
| 3/31/2019 | 6,572 | 2,428 | N/A | 2,473 | N/A |
| 12/31/2018 | 5,146 | 2,444 | N/A | 2,195 | N/A |
| 9/30/2018 | 6,365 | 1,798 | N/A | 2,033 | N/A |
| 6/30/2018 | 6,203 | 1,591 | N/A | 1,995 | N/A |
| 3/31/2018 | 6,065 | 1,428 | N/A | 1,570 | N/A |
| 12/31/2017 | 5,872 | 1,199 | N/A | 1,307 | N/A |
| 9/30/2017 | 5,517 | 1,278 | N/A | 1,118 | N/A |
| 6/30/2017 | 5,236 | 1,155 | N/A | 1,354 | N/A |
| 3/31/2017 | 4,979 | 963 | N/A | 1,784 | N/A |
| 12/31/2016 | 4,860 | 896 | N/A | 1,486 | N/A |
| 9/30/2016 | 4,732 | 797 | N/A | 1,377 | N/A |
| 6/30/2016 | 4,649 | 743 | N/A | 1,619 | N/A |
| 3/31/2016 | 4,435 | 741 | N/A | 1,477 | N/A |
| 12/31/2015 | 4,104 | 636 | N/A | 1,331 | N/A |
| 9/30/2015 | 3,808 | 571 | N/A | 1,247 | N/A |
| 6/30/2015 | 3,396 | 444 | N/A | 519 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei REGN ( 11.7% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van REGN ( 11.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.7% per jaar).
Hoge groeiwinsten: De winst van REGN zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van REGN ( 8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).
Hoge groei-inkomsten: De omzet van REGN ( 8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen REGN zal naar verwachting over 3 jaar laag zijn ( 15 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 04:49 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Regeneron Pharmaceuticals, Inc. wordt gevolgd door 53 analisten. 27 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |